Compellis Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Out of Business
- Employees
-
74
- Latest Deal Type
-
Out of Business
Compellis Pharmaceuticals General Information
Description
Developer of therapeutic drugs intended to treat obesity and related disorders. The company's therapeutic drugs block calcium channel that decreases caloric intake by reducing olfactory function, enabling patients to achieve a reduction in food intake, thereby leading to a desired weight reduction and better quality of life.
Contact Information
Website
www.compellis.comCorporate Office
- 141 PowderHouse Boulevard
- Suite 1
- Boston, MA 02144
- United States
Corporate Office
- 141 PowderHouse Boulevard
- Suite 1
- Boston, MA 02144
- United States
Compellis Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Apr-2016 | Completed | Out of Business | |||
| 1. Early Stage VC | Completed | Startup |
Compellis Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Compellis Pharmaceuticals Patents
Compellis Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20050191245-A1 | Increases amount of drug (verapamil, diltiazem, cinnarizine or nifedipine) delivered to the brain of a patient | Inactive | 27-Feb-2004 | ||
| US-20040167117-A1 | Calcium channel blockers administered into nose | Active | 18-Feb-2003 | ||
| US-7138107-B2 | Calcium channel blockers administered into nose | Inactive | 18-Feb-2003 | ||
| US-7435407-B2 | Intranasal administration of an l-type cyclic-nucleotide-gated calcium channel blocker, verapamil, amlodipine, nimodipine, israpidine; atherosclerosis, coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, gout, osteoarthritis, intertrigo, sleep apnea, hyperlipidemia | Inactive | 09-Dec-2002 | ||
| US-20070025921-A1 | Intranasal administration of an l-type cyclic-nucleotide-gated calcium channel blocker, verapamil, amlodipine, nimodipine, israpidine; atherosclerosis, coronary artery disease, hypertension, hypercholesterolemia, diabetes mellitus, gout, osteoarthritis, intertrigo, sleep apnea, hyperlipidemia | Active | 09-Dec-2002 | A61K9/0043 |
Compellis Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Compellis Pharmaceuticals FAQs
-
When was Compellis Pharmaceuticals founded?
Compellis Pharmaceuticals was founded in 2002.
-
Where is Compellis Pharmaceuticals headquartered?
Compellis Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Compellis Pharmaceuticals?
Compellis Pharmaceuticals has 74 total employees.
-
What industry is Compellis Pharmaceuticals in?
Compellis Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Compellis Pharmaceuticals a private or public company?
Compellis Pharmaceuticals is a Private company.
-
What is Compellis Pharmaceuticals’s current revenue?
The current revenue for Compellis Pharmaceuticals is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
